CME/SAM. Bleeding Risks and Response to Therapy in Patients With INR Higher Than 9. Monica B. Pagano, MD, 1 and Wayne L. Chandler, MD 2.
|
|
- Cory Doyle
- 6 years ago
- Views:
Transcription
1 Coagulation and Transfusion Medicine / Bleeding and Therapy With INR >9 Bleeding Risks and Response to Therapy in Patients With INR Higher Than 9 Monica B. Pagano, MD, 1 and Wayne L. Chandler, MD 2 Key Words: International normalized ratio; Anticoagulant treatment; Warfarin treatment CME/SAM Upon completion of this activity you will be able to: discuss mortality in different patient groups having an international normalized ratio (INR) higher than 9. list the factors associated with bleeding in patients receiving warfarin with an INR higher than 9. describe the effect of different therapies on INR for inpatients receiving warfarin with an initial INR higher than 9. The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module. The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose. Questions appear on p 616. Exam is located at Abstract An international normalized ratio (INR) higher than 9 is associated with a high risk of bleeding, yet most studies have focused on outpatients with lower INR. We retrospectively analyzed diagnosis, bleeding, treatment, and mortality in 162 patients with INR higher than 9, including inpatients and outpatients with and without warfarin treatment. Patients without anticoagulant treatment with INR higher than 9 had a poor prognosis, 67% experienced bleeding and 74% died. Among outpatients receiving warfarin with INR higher than 9, 11% had bleeding, but none died. Among inpatients receiving warfarin, 35% had bleeding and 17% died. Factors associated with bleeding were older age, renal failure, and alcohol use. Withholding warfarin or giving vitamin K treatment was ineffective at reducing the INR within 24 hours, whereas plasma infusion immediately dropped the INR to 2.4 ± 0.9. Because of underlying disease, comorbidities, and medications, hospitalized patients with INR higher than 9 may not respond quickly to withholding warfarin or vitamin K treatment, and plasma infusion may be needed to reduce INR and the risk of bleeding within 24 hours. The most significant side effect of warfarin treatment is an increased risk of bleeding. 1 Outcomes associated with major bleeding in patients taking warfarin are worse than in patients not taking warfarin. 2 International normalized ratio (INR) fluctuations are common because of drug interactions that modify warfarin metabolism, 3,4 changes in dietary vitamin K intake, 5 or unintentional errors in warfarin dosing. Close monitoring of INR is necessary to avoid both underand overanticoagulation. 6,7 INR higher than 4 has been associated with an increased risk of bleeding, 8 and the risk of intracranial hemorrhage increases approximately 2-fold for every 1 unit rise in INR. 9 INR greater than 9 is associated with a particularly high risk of bleeding, with up to 20% of patients with INR higher than 9 bleeding within the next week, fold higher than patients with INR lower than Well-controlled trials of warfarin have reported an annual risk of bleeding of about 0.5% per year, but real-world studies have found bleeding risks up to 6-fold higher. 12 Studies on correcting excessive anticoagulation with warfarin typically evaluated outpatients only and often excluded patients based on comorbidities, other medications, age, and other factors. 10,13-17 Current guidelines to correct excess vitamin K antagonist (VKA) associated anticoagulation in patients with INR higher than 10 and with no evidence of bleeding recommend giving vitamin K, and recommend 4-factor prothrombin complex concentrate rather than plasma for major VKAassociated bleeding. 18 Vitamin K treatment response has not been evaluated in hospitalized patients with INR higher than 9. We reviewed 162 patients, including both outpatients and inpatients, with an INR higher than 9, and describe herein their bleeding rates, bleeding risk factors, presence of 546 Am J Clin Pathol 2012;138: Downloaded 546 from
2 Coagulation and Transfusion Medicine / Original Article comorbidities, and response to different treatment modalities to reverse the warfarin effect. Materials and Methods The study was approved by the University of Washington (Seattle) human subjects office. A retrospective analysis was performed of patient charts with INR values higher than or equal to 9 during the period January 1, 2008, to June 10, Inpatients and outpatients were included and incomplete charts were excluded, resulting in a total of 162 patients in the study. Data Collection Data included the following: gender, age, reason for admission, INR collection date, initial INR result, and where available, INR result 24 hours after treatment, patient location, anticoagulation indication and duration, warfarin dose, platelet count, history of bleeding, chronic heart failure, renal failure, stroke, hypertension, cancer, and alcohol use. Alcohol use was defined as the intake of 1 or more alcoholic beverages per day. Treatments included warfarin cessation, vitamin K administration, and plasma infusion. One patient with trauma received recombinant factor VII in addition to plasma, and none of the patients received factor concentrates. Statistical Analysis A logistic model was used to estimate the effect of several predictors on the probability of bleeding. The relationship between the predictors and the occurrence of bleeding was assumed to follow a nonlinear, logistic function based on the weights of the 10 variables used to predict the probability of bleeding, namely, male sex, age, renal failure, congestive heart failure, hypertension, alcohol use, bleeding history, cancer, stroke, and warfarin dose (in log scale). Results are given as the mean ± standard deviation (SD) unless otherwise noted. The unpaired t test was used to determine individual differences between groups. Results Patient Characteristics Of 162 patients with INR higher than 9, 36 (22%) were outpatients and 126 (78%) were inpatients. Table 1 shows anticoagulant and fibrinolytic therapy in patients with INR higher than 9. All of the outpatients with INR higher than 9 were receiving warfarin. Of the inpatients with INR higher than 9, 37% were receiving warfarin; 15%, direct thrombin inhibitors; 3%, tissue plasminogen activator; and 45% were not receiving any anticoagulant or fibrinolytic therapy. Patients with INR higher than 9 receiving warfarin were on average 59 years old, with a mean INR of 10.6 ± 1.3. Patients with INR higher than 9 not receiving warfarin were on average 50 years old, with a mean INR of 11.0 ± 1.3. The lower average age of patients with INR higher than 9 not receiving warfarin primarily reflects the population of patients with trauma with INR higher than 9 with an average age of 30 years. Diagnosis, Bleeding, Treatment, and Mortality in Patients Not Receiving Warfarin All patients not receiving warfarin with INR higher than 9 were inpatients. Table 2 shows the primary diagnosis and number of patients with reported bleeding. The majority of patients (71%) not receiving warfarin who had an INR higher than 9 were also not receiving any other anticoagulant or fibrinolytic therapy. These patients typically had some form of liver failure, shock, or trauma. Of the patients with acute or chronic liver failure and INR higher than 9, 46% had bleeding, typically treated with blood products, and 64% died. All patients undergoing liver transplantation with INR higher than 9 reported bleeding and were treated with blood products, of whom 18% died. Patients were admitted with shock and INR Table 1 Anticoagulant and Fibrinolytic Therapy in Patients With INR Higher Than 9 Group Anticoagulant No. (% of Total) Outpatients Warfarin 36 (22) Inpatients Warfarin 46 (28) Inpatients Direct thrombin inhibitor * 19 (12) Inpatients Tissue plasminogen activator 4 (3) Inpatients None 57 (35) Total 162 (100) INR, international normalized ratio. * Three patients received argatroban, while 16 received bivalirudin. Table 2 Diagnosis and Bleeding for Inpatients Not Receiving Warfarin With INR Higher Than 9 No. (% Bleeding, No. Diagnosis of Total) (% With Diagnosis) Liver failure/liver transplant 22 (28) 16 (73) Shock 21 (26) 9 (43) Trauma 15 (19) 14 (93) HIT 13 (16) 4 (31) Thrombosis * 9 (11) 3 (33) Total 80 (100) 46 (58) HIT, heparin-induced thrombocytopenia; INR, international normalized ratio. * Thrombosis included ischemic stroke (n = 3), intracardiac thrombosis/disseminated intravascular coagulation (n = 1), limb ischemia (n = 3), and massive pulmonary embolism (n = 2). Downloaded from Am J Clin Pathol 2012;138:
3 Pagano and Chandler / Bleeding and Therapy With INR >9 higher than 9 for a number of reasons, including resuscitation after cardiac arrest, sepsis, heart failure, and drug overdose. Of patients with shock, 43% were reported to have bleeding, which was treated with blood products, but 90% died. Essentially all patients with trauma with INR higher than 9 had bleeding, of whom most were treated with blood products, and 1 with plasma and recombinant factor VIIa, but all died. Overall, INR higher than 9 in patients not receiving an anticoagulant was a bad prognostic sign; of these, 67% experienced bleeding and 74% died. The patients diagnosed with heparin-induced thrombocytopenia and INR higher than 9 were all receiving a direct thrombin inhibitor (3 received argatroban and 16 bivalirudin), 31% reported bleeding, and 23% died (1 patient of heart failure and 2 of pulmonary embolism). Patients with no bleeding were generally treated by stopping the drug. Most of the patients with bleeding with a diagnosis of heparin-induced thrombocytopenia were undergoing cardiopulmonary bypass using the direct thrombin inhibitor bivalirudin. All of these patients were treated with blood products during surgery. The inpatients not receiving warfarin with thrombosis and INR higher than 9 were receiving a direct thrombin inhibitor or fibrinolytic therapy, 33% reported bleeding while 11% died. Typically they were treated with a combination of stopping the drug and blood products. Diagnosis, Bleeding, and Treatment in Patients Receiving Warfarin Of the patients receiving warfarin who had an INR higher than 9, 44% were outpatients. Of these, 11% reported bleeding that was typically treated with vitamin K. Outpatients with INR higher than 9 who did not have bleeding were treated by withholding warfarin in 36% and vitamin K in 64%. Platelet counts were available on 17 of 36 outpatients with INR higher than 9, all of which were normal (328 ± /µl [328 ± /L]). Follow-up on the outpatients was limited, but none died soon after the high INR was noted and none received blood products. The association between common comorbidities and bleeding for all 82 patients receiving warfarin with INR higher than 9 is shown in Table 3. The factors associated with an increased risk of bleeding were older age, the presence of renal failure, and alcohol use. In contrast, a history of cancer was associated with a reduced risk of bleeding. Treatment of Inpatients Receiving Warfarin With INR Higher Than 9 Sixteen of the 46 inpatients receiving warfarin with INR higher than 9 were admitted for bleeding, whereas the other 30 patients were admitted for other reasons including infection or sepsis, thrombosis, cancer, and congestive heart failure Table 4. Platelet counts were available on all inpatients with INR higher than 9 (232 ± /µl [232 ± /L]). Only 3 inpatients with INR higher than 9 had platelet counts less than /µl ( /L), of whom only 1 had bleeding (retroperitoneal hemorrhage associated with an abdominal aortic aneurysm). Overall mortality was 17% for the inpatients receiving warfarin with INR higher than 9. Figure 1 shows the effect of different forms of treatment on inpatients taking warfarin who had an INR higher than 9. There was no difference in the initial INR for the 3 treatment groups (withholding warfarin, vitamin K administration, and plasma infusion). On average, patients treated with vitamin K were given 5 mg (range, 1-10 mg). On average, patients treated with plasma were given 4 units of fresh frozen plasma (range, 2-6 units). There was no significant difference in the INR after 24 hours of treatment between withholding warfarin and vitamin K administration (P =.20). Infusion of plasma significantly reduced the INR compared with vitamin K or withholding warfarin (P <.001). Among the inpatients receiving warfarin with INR higher than 9 and bleeding at admission, 1 was treated by withholding warfarin (6%), 2 were treated with vitamin K (13%), and 13 received plasma infusion (81%). None of these patients experienced rebleeding and there were no deaths related to Table 3 Comorbidities and Other Factors Associated With Increased Bleeding in Patients Receiving Warfarin With INR Higher Than 9 No. (% Association With Comorbidities (n = 82) of Total) Increased Bleeding Alcohol use 22 (27.2) Renal dysfunction 29 (35.8) Cancer 20 (24.7) NS Congestive heart failure 26 (32.1) NS History of bleeding 9 (11.1) NS History of stroke 9 (11.1) NS Other Factors Age Male 41 (50) NS INR, international normalized ratio; NS, not significant. Table 4 Diagnosis for Inpatients Receiving Warfarin With INR Higher Than 9 Diagnosis No. (% of Total) Bleeding 16 (35) Infection/sepsis 9 (20) Thrombosis* 5 (11) Cancer 4 (9) Congestive heart failure 3 (6) High INR 3 (6) Other 6 (13) Total 46 (100) INR, international normalized ratio; NS, not significant. * Thrombosis included ischemic stroke (n = 5) and limb ischemia (n = 1). 548 Am J Clin Pathol 2012;138: Downloaded 548 from
4 Coagulation and Transfusion Medicine / Original Article bleeding episodes. For inpatients receiving warfarin with INR higher than 9 but no bleeding at admission, treatment included withholding warfarin in 3 (10%), vitamin K in 17 (57%), and plasma infusion in 10 (33%). There was 1 episode of fatal intracranial hemorrhage in the vitamin K group in a patient with INR higher than 9 after treatment. INR Discussion Supratherapeutic INR is a common occurrence in patients receiving warfarin treatment. 19 Garcia et al 11 showed that the risk of major bleeding in outpatients with an INR of 5 to 9 was 0.5% in the first 2 weeks, compared with 10% when the INR was higher than 9. Crowther et al 10 reported that up to 21% of patients with INR higher than 9 experienced bleeding within the next 7 days. In this study, we evaluated 162 patients with INR higher than 9 during a 17-month period. We separated our data into 2 major groups, patients with INR higher than 9 who were either receiving warfarin or not receiving warfarin. We further separated the group not receiving warfarin into those receiving another anticoagulant or fibrinolytic drug vs those not taking any other antithrombotic medications. For outpatients (all receiving warfarin), the incidence of bleeding was 11%, similar to the rate seen in prior studies. 11 The incidence of bleeding in all patients with INR higher than 9 was 38%, higher than in previous studies. This difference reflects the inclusion of hospitalized patients with INR higher than 9, including patients receiving warfarin, those receiving other anticoagulants, and those receiving no anticoagulants. Prior studies have reported that older age was a risk factor for bleeding with warfarin therapy and that alcohol use was associated with an increased risk of intracranial hemorrhage. 9,20 We found that in patients with INR higher than 9 who were receiving warfarin, older age, renal failure, and alcohol use were all associated with an increased risk of bleeding. Patients with INR higher than 9 not receiving warfarin or any other anticoagulants generally had a severe underlying illness, typically shock after resuscitation for cardiac arrest, severe trauma, liver failure, or liver transplantation. These patients had a high rate of bleeding (67%), were typically treated with plasma infusion, and had a high mortality rate (74%). Although bleeding was common in this group, patients typically died of other causes. The other group of patients with INR higher than 9 and not receiving warfarin were patients receiving direct thrombin inhibitors or fibrinolytic therapy. Bleeding was still common in this group (32%), but the mortality rate was lower (18%). Prolonged INR in patients receiving direct thrombin inhibitors may be because of a combination of direct thrombin inhibitor effects and low factor levels. Determining the specific cause of INR higher than 9 in Withhold Warfarin Vitamin K Plasma Infusion Figure 1 Effect of different therapies on international normalized ratio (INR) for inpatients receiving warfarin with INR higher than 9. The black bars show the mean and standard deviation for the initial INR. The gray bars show INR 24 hours after the start of different treatments. patients receiving direct thrombin inhibitors requires separate specific tests for both direct thrombin inhibitor effect that is not affected by low factor levels, such as a plasma diluted thrombin time, and for factor levels not affected by direct thrombin inhibitors, such as a chromogenic factor X level Vitamin K can successfully correct an excess of anticoagulation; the response depends on the dose of vitamin K and on the presence of normal liver function. Previous studies evaluating vitamin K response typically included only outpatients and often excluded patients with renal and liver dysfunction. 10,13-17 In this study, we tracked the effect of treatment for INR higher than 9 in hospitalized patients receiving warfarin. We found that withholding warfarin had no effect on INR in the first 24 hours and that treatment with vitamin K produced a small decrease in INR by 24 hours, but that the effect was highly variable among patients and that the INR at 24 hours was not significantly different from withholding warfarin. A prior study on outpatients receiving VKA with INR higher than 10 used INR of less than 5 as a indication of successful treatment with vitamin K. 14 Using this criterion, withholding warfarin was unsuccessful at reversing INR higher than 9 for inpatients and vitamin K was successful in only 8 (42%) of 19 patients. In contrast, infusion of plasma produced an immediate decrease in INR, with significantly lower INR at 24 hours than did withholding warfarin or vitamin K administration. All of the patients with INR higher than 9 treated with plasma had an INR less than 5 after treatment (mean INR, 2.4). Conclusions from this study are limited by the observational and not randomized prospective nature of the data, lack of protocol for treatment decisions made by individual physicians, and potential influence of confounding variables. Downloaded from Am J Clin Pathol 2012;138:
5 Pagano and Chandler / Bleeding and Therapy With INR >9 Care needs to be taken when choosing a therapy for INR higher than 9 in hospitalized patients. Because of other comorbidities such as liver disease and other treatments such as antibiotics that potentially prolong INR, 24 hospitalized patients may not respond to withholding warfarin or administration of vitamin K as quickly as expected from studies based on carefully selected outpatients. A decision on whether to use plasma infusion to reverse INR higher than 9 should include consideration of the high risk of bleeding, up to 20% in the next 7 days with INR higher than 9, other comorbidities, medications, and age. What works in an otherwise healthy outpatient may not be sufficient in an elderly inpatient with multiple medical problems. From the 1 Department of Laboratory Medicine, University of Washington, Seattle, WA, and 2 the Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, Texas. Address reprint requests to Dr Chandler: Methodist Pathology Associates, 6565 Fannin, Suite B-490, Houston, TX, 77030; wlchandler@tmhs.org. References 1. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multi-center study Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993;118: Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120: Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy. 1997;17: Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165: Rohde LE, de Assis MC, Rabelo ER. Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care. 2007;10: Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis. 1998;5(suppl 1): Shalev V, Rogowski O, Shimron O, et al. The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation. Thromb Res. 2007;120: Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;29: Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120: Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin, a randomized trial. Ann Intern Med. 2009;150: Garcia DA, Regan S, Crowther M, et al. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006;47: Eerenberg ML, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost. 2011;9: Crowther MA, Garcia D, Ageno W, et al. Oral vitamin K effectively treats international normalized ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost. 2010;104: Gunther KE, Conway G, Leibach L, et al. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res. 2004;113: Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (Vitamin K1) in patients with excessive anticoagulation. Arch Intern Med. 2003;163: Baker P, Gleghorn A, Tripp T, et al. Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Haematol. 2006;133: Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med. 1998;158: Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e152S-e154S. 19. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129: Qureshi AI, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344: Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007;98: Rosborough TK, Shepherd MF. Unreliability of the international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulants. Pharmacotherapy. 2004;24: Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy. 2005;25: Penning-Van Beest FJ, Koerselman J, Herings RMC. Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. J Thromb Haemost. 2008;6: Am J Clin Pathol 2012;138: Downloaded 550 from
Chapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationWARFARIN REVERSAL GUIDELINE
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationMANAGEMENT OF OVER-ANTICOAGULATION. Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas
MANAGEMENT OF OVER-ANTICOAGULATION Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas Risk of Intracranial Hemorrhage in Outpatients (From Management of Oral Anticoagulant
More informationWarfarin Management-Review
Warfarin Management-Review December 18, 2012 Elaine M. Hylek, MD, MPH Director, Thrombosis Clinic and Anticoagulation Service Boston University Medical Center Areas for Discussion Implications of time
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationDeveloped for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG)
Approved by NPPEAG 18 December 2018 Reviewed 18 December 2018 To be reviewed 18 December 2020 Developed for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG) Protocol for the Reversal
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationThe Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy
Journal of the American College of Cardiology Vol. 47, No. 4, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.09.058
More informationUnstable INR Has Implications for Healthcare Resource Use. Janssen Pharmaceuticals, Inc.
Unstable INR Has Implications for Healthcare Resource Use Janssen Pharmaceuticals, Inc. Stable INR is essential for effective anticoagulation treatment Achieving a stable international normalized ratio
More informationOnline Supplementary Data. Country Number of centers Number of patients randomized
A Randomized, Double-Blind, -Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular
More informationSign up to receive ATOTW weekly -
ANTICOAGULATION & INTRACRANIAL BLEEDS - MANAGEMENT OF THE ANTICOAGULATED PATIENT PRESENTING WITH INTRACRANIAL HAEMORRHAGE ANAESTHESIA TUTORIAL OF THE WEEK 82 12 th January 2008 Rebecca Appelboam, Exeter,
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationORIGINAL INVESTIGATION. Aharon Lubetsky, MD; Hagith Yonath, MD; David Olchovsky, MD; Ronen Loebstein, MD; Hillel Halkin, MD; David Ezra, MD
ORIGINAL INVESTIGATION Comparison of Oral vs Intravenous Phytonadione (Vitamin K 1 ) in Patients With Excessive Anticoagulation A Prospective Randomized Controlled Study Aharon Lubetsky, MD; Hagith Yonath,
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationUse of Anticoagulants in Geriatrics: Current Evidence and Special Considerations
Use of Anticoagulants in Geriatrics: Current Evidence and Special Considerations Aryn You, PharmD Assistant Professor, Pharmacy Practice The Daniel K. Inouye College of Pharmacy Aida Wen, MD Associate
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationDespite the approval of multiple novel agents,
Hosp Pharm 2015;50(1):018 024 2015 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj5001-018 Critical Care An Evaluation of Intravenous Vitamin K for Warfarin Reversal: Are Guideline
More informationHuman Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC
Human Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC Ayman Kafal Medical Affairs, Leader CSL Behring Canada 1 Prothrombin Complex
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationManagement of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support
More informationHeparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital
Heparin-Induced Thrombocytopenia Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital Heparin-induced thrombocytopenia (HIT) A serious concern associated with thrombosis development following
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationAnticoagulant-related Bleeding Management Order Set
Triage This icon represents guidance recommended by Thrombosis Canada Priority: Determine Bleeding Acuity: Minor, Moderate or Severe Bleeding Check one of the Following Levels of Bleeding Acuity (check
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationWarfarin is a commonly used anticoagulant for the primary
CASE REPORT Warfarin Re-initiation Gone Awry: A Case of Inadvertent Overdose Mandating Critical INR Management Tammy J Bungard and Angela Gee NTRODUCTION Warfarin is a commonly used anticoagulant for the
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationDr Shikha Chattree Haematology Consultant Sunderland Royal infirmary
Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Increasing use of Novel Oral Anticoagulants (NOACs) in the management of prophylaxis and management of venous thromboembolism and in
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationPage 1 of 6. Low 1 (score 0-3) Monitor platelets and signs and symptoms of thrombosis and continue heparin
Page 1 of 6 Estimate probability of HIT using the Four T s 1 Low 1 (score 0-3) Intermediate 1 (score 4-5) or High 1 (score 6-8) Monitor platelets and signs and symptoms of thrombosis and continue heparin
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More informationAssessing thrombocytopenia in the intensive care unit: The past, present, and future
Assessing thrombocytopenia in the intensive care unit: The past, present, and future Ryan Zarychanski MD MSc FRCPC Sections of Critical Care and of Hematology, University of Manitoba Disclosures FINANCIAL
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationSafety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels
CLINICAL RESEARCH STUDY Safety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels Imdad Ahmed, MBBS, a,b Elie Gertner, MD a,b a Department of Internal Medicine,
More informationDeterminants of effective, safe and convenient vitamin K antagonist use Kooistra, Hilde Afra Margaretha
University of Groningen Determinants of effective, safe and convenient vitamin K antagonist use Kooistra, Hilde Afra Margaretha IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationActive date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:
Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist
More informationBleeding Complications in Patients Receiving Direct Oral Anticoagulant Therapy in the Post Clinical Trial General Practice
American Journal of Clinical and Experimental Medicine 2017; 5(3): 64-68 http://www.sciencepublishinggroup.com/j/ajcem doi: 10.11648/j.ajcem.20170503.12 ISSN: 2330-8125 (Print); ISSN: 2330-8133 (Online)
More informationReducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA
DECEMBER 21 VOL. 27 SUPPL. 1 A SUPPLEMENT TO www.fedprac.com Reducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA Diagnosing and Treating Atrial Fibrillation in the VHA
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationComplicanze aritmiche in riabilitazione dopo CCH.
Complicanze aritmiche in riabilitazione dopo CCH www.fisiokinesiterapia.biz Post-Operative Atrial Fibrillation The rate of AF after cardiac surgery in the 1970s was about 10%, and is now consistently at
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More informationHow to reverse warfarin
Page 1 of 5 How to reverse warfarin Index: Anticoagulation Original article by: Michael Tam Resources Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationComplicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital
Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationCEDR 2018 QCDR Measures for CMS 2018 MIPS Performance Year Reporting
ACEP19 Emergency Department Utilization of CT for Minor Blunt Head Trauma for Aged 18 Years and Older Percentage of visits for aged 18 years and older who presented with a minor blunt head trauma who had
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationRecombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD
Recombinant Activated Factor VII: Useful Department of Surgery Grand Rounds 11/8/10 David Mauchley MD Hemostasis and Coagulation Traditional cascade model Two convergent pathways Series of proteolytic
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationIndex. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.
Hematol Oncol Clin N Am 19 (2005) 203 208 Index Note: Page numbers of article titles are in boldface type. A Abciximab, as an antiplatelet agent, 93 94 Acute coronary syndromes, use of antiplatelet drugs
More informationClinical aspects of venous thromboembolism in special patient populations Bleker, S.M.
UvA-DARE (Digital Academic Repository) Clinical aspects of venous thromboembolism in special patient populations Bleker, S.M. Link to publication Citation for published version (APA): Bleker, S. M. (2017).
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationGUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE
2018 UPDATE QUICK SHEET 2018 American Heart Association GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE A Summary for Healthcare Professionals from the American Heart Association/American
More informationRecombinant Activated Factor VII in Controlling Bleeding in Non-Hemophiliac Patients
Bahrain Medical Bulletin, Vol. 34, No. 3, September 2012 Recombinant Activated Factor VII in Controlling Bleeding in Non-Hemophiliac Patients Ali A Faydhi, MRCP, EDIC* Adel M Al-Shabassy, MD** Yasser A
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationNon-Obvious, Post-Traumatic, Life-Threatening Bleeding in Two Elderly Patients
Online ahead-of-print. Page numbers NOT for citation purposes. Non-Obvious, Post-Traumatic, Life-Threatening Bleeding in Two Elderly Patients CASE REPORT DOI: 10.1515/jccm-2017-0012 Rafael García Carretero
More information>>FAST TRACK<< Hemostasis has three key components: platelets, the plasma coagulation. cascade, and the blood vessel wall (endothelium).
How to Reverse an Antithrombotic Agent The authors review options and precautions to consider when you need to restore hemostasis in a patient receiving an anticoagulant, antiplatelet, or fibrinolytic
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationIntraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL
Intraoperative haemorrhage and haemostasis Dr. med. Christian Quadri Capoclinica Anestesia, ORL Haemostasis is like love. Everybody talks about it, nobody understands it. JH Levy 2000 Intraoperative Haemorrhage
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationThe following content was supplied by the author as supporting material and has not been copy-edited or verified by JBJS.
Page 1 The following content was supplied by the author as supporting material and has not been copy-edited or verified by JBJS. Appendix TABLE E-1 Care-Module Trigger Events That May Indicate an Adverse
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationPlatelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment
Objectives IIb/IIIa, Vitamin K, and Direct Thrombin Inhibition in Cardiology Michael Gulseth, Pharm. D., BCPS Assistant Professor, Duluth Pharmacy 6122 February 14, 2005 Describe the pharmacology, kinetics,
More informationIntroduction. Blood Pressure
Introduction Spontaneous intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality worldwide [1]. Of a number of factors that have been linked to ICH (e.g., higher rates in Asians and
More informationEverything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science
Everything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science Center at San Antonio Department of Pharmacotherapy
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationDirect oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation
J Thromb Thrombolysis (2016) 42:573 578 DOI 10.1007/s19-016-1410-z Direct oral anticoagulant use and the incidence of in the very elderly with atrial fibrillation Fatima Khan 1,2 Hans Huang 2 Yvonne H.
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More information